JNJ (Johnson & Johnson) Stock Analysis - Financials

Johnson & Johnson (JNJ) is a publicly traded Healthcare sector company. As of May 20, 2026, JNJ trades at $230.00 with a market cap of $551.06B and a P/E ratio of 26.42. JNJ moved -0.35% today. Year to date, JNJ is +10.92%; over the trailing twelve months it is +50.83%. Its 52-week range spans $140.68 to $251.71. Analyst consensus is buy with an average price target of $264.75. Rallies surfaces JNJ's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are JNJ's key financials?

JNJ financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. JNJ recently traded at $230.00. Market cap is $551.06B. P/E ratio is 26.42. Revenue is $96.36B.

JNJ Key Metrics

Key financial metrics for JNJ
MetricValue
Price$230.00
Market Cap$551.06B
P/E Ratio26.42
EPS$8.73
Dividend Yield1.34%
52-Week High$251.71
52-Week Low$140.68
Volume3.37M
Avg Volume0
Revenue (TTM)$96.36B
Net Income$21.04B
Gross Margin67.82%

JNJ Annual Financials

YearRevenueNet IncomeEPS
2025$94.19B$26.80B$11.13
2024$88.82B$14.07B$5.84
2023$85.16B$35.15B$13.88
2022$93.78B$20.88B$7.93

Latest JNJ News

Recent JNJ Insider Trades

  • Decker Robert J sold 4.08K (~$1.01M) on Feb 27, 2026.
  • Schmid Timothy sold 1.32K (~$324.76K) on Feb 20, 2026.
  • Schmid Timothy sold 13.63K (~$3.33M) on Feb 18, 2026.

JNJ Analyst Consensus

18 analysts cover JNJ: 0 strong buy, 12 buy, 6 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $264.75.

Common questions about JNJ

What are JNJ's key financials?
JNJ financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. JNJ recently traded at $230.00. Market cap is $551.06B. P/E ratio is 26.42. Revenue is $96.36B.
Is JNJ research on Rallies investment advice?
No. Rallies provides research, data, and educational context for JNJ. It does not provide personalized investment advice.
JNJ

Johnson & Johnson